Orthovita, Inc. (NASDAQ:VITA) will hold a conference call on Tuesday, May 4, 2010 to discuss the financial results for the first quarter of 2010. The call will begin at 8:30 am ET that morning and will be joined by Orthovita president and chief executive officer Antony Koblish, and senior vice president and chief financial officer Nancy Broadbent. To join the call, dial 888.815.2919, or 706.643.3675 for non US callers. The conference identification number is 67873938. Callers are urged to dial in ten minutes prior to the scheduled start of the call.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
Orthovita, Inc. (Orthovita) is a specialty spine and orthopedic company with a portfolio of orthobiologic and biosurgery products. Its orthobiologic platform includes products for the fusion, regeneration and fixation of human bone. Its orthobiologic products are based on its Vitoss Bone Graft Substitute technology and include the Imbibe Bone Marrow Aspiration System used with Vitoss. Vitoss is the synthetic bone graft in the United States. Its orthobiologic products also include Cortoss Bone Augmentation Material and the Aliquot Delivery System used with Cortoss. The Company’s biosurgery products include Vitagel Surgical Hemostat, Vitasure Absorbable Hemostat, and the CellPaker Plasma Collection System used in conjunction with Vitagel, and other accessories and delivery products that complement Vitagel product.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
